
Following the announcement of positive top-line results from its open-label Phase 2a trial, the stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has seen a 21.94% rise in after-hours trading on Tuesday.
Check out the current price of ACRS stock here.

Following the announcement of positive top-line results from its open-label Phase 2a trial, the stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has seen a 21.94% rise in after-hours trading on Tuesday.
Check out the current price of ACRS stock here.